Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16901904 | 0.97 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672267 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672268 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16901925 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16901932 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16901896 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL20159053 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL10565137 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL16901882 | 0.90 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNANPC1RAB9AMEN1 | |
| SCHEMBL18672266 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2022263594-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9919064-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170258947-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9161997-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2015-10-20 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150165074-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8936777-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140328757-A1 | COMPOSITIONS COMPRISING ASCORBIC ACID AND AN IMAGING AGENT AND RELATED METHODS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20130064769-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | SMN1; SMN2 420/4885LMNA 1473/4885NPC1 272/4885 |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885NPC1 350/4885 |
| US-20180133347-A9 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | MCOLN1, CNR1, SLC5A7 | SMN1; SMN2 774/4885LMNA 4556/4885NPC1 169/4885 |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SMN1; SMN2 148/4885LMNA 1311/4885NPC1 988/4885 |
| US-10022462-B2 | Methods and apparatus for synthesizing imaging agents, and intermediates thereof | TNNI3, FABP3, MPI | SMN1; SMN2 2628/4885LMNA 3154/4885NPC1 1259/4885 |
| US-20110091374-A1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | FABP7, MKI67, SLC5A7 | SMN1; SMN2 855/4885LMNA 4308/4885NPC1 181/4885 |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SMN1; SMN2 148/4885LMNA 1311/4885NPC1 988/4885 |
| US-20150165074-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | SMN1; SMN2 2628/4885LMNA 3154/4885NPC1 1259/4885 |
| US-20130064769-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | SMN1; SMN2 2628/4885LMNA 3154/4885NPC1 1259/4885 |
| US-20140328757-A1 | COMPOSITIONS COMPRISING ASCORBIC ACID AND AN IMAGING AGENT AND RELATED METHODS | PLPBP, PNPO, PROC | SMN1; SMN2 739/4885LMNA 657/4885NPC1 1619/4885 |
| US-20170258947-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | SMN1; SMN2 2628/4885LMNA 3154/4885NPC1 1259/4885 |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885NPC1 350/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885NPC1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.